Potassium canrenoate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Potassium canrenoate
Potassium canrenoate.svg
Clinical data
Other namesSC-14266
AHFS/Drugs.comInternational Drug Names
Routes of
ATC code
Pharmacokinetic data
ExcretionRenal and fecal
  • potassium 3-[(8R,9S,10R,13S,14S,17R)-
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.016.868 Edit this at Wikidata
Chemical and physical data
Molar mass396.568 g·mol−1
3D model (JSmol)
  • [K+].[O-]C(=O)CC[C@]3(O)CC[C@H]2[C@@H]4/C=C\C1=C\C(=O)CC[C@@]1([C@H]4CC[C@@]23C)C
  • InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1 checkY
 ☒NcheckY (what is this?)  (verify)

Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), also known as aldadiene kalium,[1] the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.[2] Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body.[3][4]

Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for parenteral administration (specifically intravenous)[4][5] as opposed to oral administration.[6]

In the UK it is unlicensed and only used for short term diuresis in oedema or heart failure in neonates or children under specialist initiation and monitoring.

See also[edit]


  1. ^ Hans Selye (17 April 2013). Hormones and Resistance: Part 1 and. Springer Science & Business Media. pp. 186–. ISBN 978-3-642-65192-2.
  2. ^ R.A. Hill; H.L.J. Makin; D.N. Kirk; G.M. Murphy (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.
  3. ^ Alfred Burger; Manfred E. Wolff (1996). Burger's Medicinal Chemistry and Drug Discovery: Therapeutic agents. Wiley. ISBN 978-0-471-57557-3.
  4. ^ a b Carl Waldmann; Neil Soni; Andrew Rhodes (27 November 2008). Oxford Desk Reference: Critical Care. OUP Oxford. pp. 187–. ISBN 978-0-19-922958-1.
  5. ^ H. Jaap Bonjer (21 June 2017). Surgical Principles of Minimally Invasive Procedures: Manual of the European Association of Endoscopic Surgery (EAES). Springer. pp. 136–. ISBN 978-3-319-43196-3.
  6. ^ Kolkhof P, Bärfacker L (2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". J. Endocrinol. 234 (1): T125–T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.